Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
205 hedge funds and large institutions have $3.41B invested in Amicus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 77 increasing their positions, 54 reducing their positions, and 27 closing their positions.
230% more call options, than puts
Call options by funds: $26.9M | Put options by funds: $8.15M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
56% more capital invested
Capital invested by funds: $2.18B → $3.41B (+$1.23B)
43% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 54
37% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 27
5% more funds holding
Funds holding: 195 → 205 (+10)
10.26% less ownership
Funds ownership: 122.29% → 112.02% (-10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$138M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.4M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$25.7M |
| 5 |
Millennium Management
New York
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$36.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.8M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$20.1M |
| 4 |
Morgan Stanley
New York
|
-$17.2M |
| 5 |
Jennison Associates
New York
|
-$14.7M |
FOLD Hedge Fund Activity: Q1 2019 in Review
205 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2019, worth a combined $3.41B — up 56% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new FOLD positions and 27 closed out — a net gain of 10 holders — while 77 added to existing stakes and 54 trimmed.
The largest buyer was Redmile Group, adding an estimated $138M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $36.4M sold.
- 205 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2019, up from 195 in Q4 2018.
- Funds reported $3.41B of Amicus Therapeutics stock for Q1 2019, up 56% quarter-over-quarter.
- 37 funds opened new Amicus Therapeutics positions in Q1 2019 and 27 closed out, a net change of +10 holders.
- The largest Amicus Therapeutics buyer in Q1 2019 was Redmile Group, an estimated $138M added.
- The largest Amicus Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $36.4M sold.
Based on aggregated 13F filings for Q1 2019.